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Background on MEND
Role players in the global effort to combat the three main “diseases of
poverty”(malaria, TB, and HIV/AIDS)
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Background on MEND
MEND was founded to fill the gap in global effort to combat the three
main “diseases of poverty”
PRIVATE FUNDING SOURCES

ACADEMIC/
RESEARCH
INSTITUTIONS

•

•
GLOBAL
PHARMA

Only 13 of the 1,223 drugs
developed since 1975 have been for
neglected diseases*
Since 1990, thousands of articles on
“breakthrough” scientific
discoveries in the primary diseases
of poverty (HIV, Malaria, TB) have
been published; however, no
vaccine products have been
approved in these areas since 1921**
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Butler, D et al. (2007) “Lost
in Translation”,
Nature. 449, 158
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Background on MEND
Bridging the gap:
• We are a 501(c)3 not-for-profit devoted to the successful development and
manufacture of affordable and effective vaccines and therapies for diseases
of poverty with characteristics that allow their widespread use and
sustainability
• We do this by incubating (and subsequently applying) emerging and
advanced delivery and manufacturing technologies to drug and vaccine
candidates for diseases to make them well-suited for the daunting economic
and logistical constraints of the developing world
.

www.medicineinneed.org

Focus on TB
The global tuberculosis (TB) epidemic:
• 14.6 million chronic and active cases in 2008 *
• 1.8 million deaths
• 500 000 cases of MDR TB
• 31% of cases in Africa
• In terms of total numbers of cases in 2008:
 India (2.0 million)
 China (1.3 million)
 Indonesia (0.53 million)
 Nigeria (0.46 million)
 South Africa (0.46 million)
* WHO (2009) “Global tuberculosis control”

Focus on TB
Challenges to combating TB in high burden countries:
• Limited access to drugs and vaccines
• Increasing levels of drug resistance
• Toxicity of drugs for MDR TB
• Duration of treatment, patient default
• Largely ineffective vaccine against pulmonary TB in adults
• Limitations imposed by current diagnostics
• Lack of incentives for manufacturers
• Cost and risks associated with injections
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BCG – The current TB vaccine
Mycobacterium bovis Bacille Calmette-Guerin (BCG):
• Developed by Calmette & Guérin (1906-1921)
• The most widely-used childhood vaccine (>100 million doses/year)
• Delivered intradermally
• No new TB vaccine in 88 years
• Requires cold-chain to ensure potency of vaccine
• Efficacy varies from 0 – 80%

BCG – The current TB vaccine
Variability is due to several reasons: *
• Genetic variability of vaccinated individuals;
• Unique characteristics of environmental mycobacteria
• Differences in immunization schedules and doses of BCG
• BCG strains differing in their genetic, biochemical
• and immunological characteristics;
• Variations in vaccine production – effect of lyophilization

* Dietrich, G et al. (2002) Journal of Biotechnology. 96, 259

BCG – The current TB vaccine
Variability is due to several reasons: *
• Genetic variability of vaccinated individuals;
• Unique characteristics of environmental mycobacteria
• Differences in immunization schedules and doses of BCG
• BCG strains differing in their genetic, biochemical
and immunological characteristics;
• Variations in vaccine production – effect of lyophilization

MEND aims to address most of these issues by utilizing an advanced
and innovative approach to formulating BCG vaccine

* Dietrich, G et al. (2002) Journal of Biotechnology. 96, 259

The Mend solution: Targeting BCG to the lung

•
•
•
•
•
•

Natural route of infection of TB
Hypothesis: immunization via lungs may lead to greater immunity
Large exposed surface area
Elimination of risks associated with needle use
Mucosal and/or systemic immunity
Noninvasive – better patient adherence

The Mend solution: Targeting BCG to the lung
Advantages of needle-free vaccination: *

• Safety
• Compliance
• Cost

• Training of healthcare workers
• Cold chain

* Giudice, E et al. (2006) Advanced Drug Delivery Reviews. 58, 68

Spray drying: a process to engineer particles for
inhalation
• David Edwards at Harvard University pioneered the application of
spray drying in formulating drugs for inhalation

• Large Porous Particles: microparticles are geometrically large (dg = 5
-10 μm) but with a low mass density ( < 0.4 g/cm3) for optimal
delivery to the lungs (da = 1–5 μm) *
• Applied to TB drugs:




Para-aminosalicylic acid (Tsapis N, et al. (2003) Tuberculosis. 83, 379)
Capreomycin (Garcia-Contreras L, et al. (2007) AAC. 51, 2830)
PA-824 (Sung JC, et al. (2009) AAC. 53, 1338)

* Edwards DA, et al. (1997) Science. 276, 1868

Spray drying: a process to engineer particles for
inhalation
• Single-step dehydration technique used in the food, pharmaceutical
and agricultural industries
• Solvent carrying solubilized substances atomized through a nozzle
• Rapid drying of droplets in contact with heated gas
• Separation of product using cyclone
• Control of particle size:
 inlet temperature
 flow rate
 excipient concentration

• Evaporation rates control particle density and thus aerodynamic
diameter (Optimum particle size for lung delivery is 1-5 μm)

Spray drying: a process to engineer particles for
inhalation
Lyophilization

Spray drying

• Batch process

• Continuous process

• High capital/ops costs

• Low capital/ops costs

• Requires cold storage

• Retain organism activity by
controlled drying

• Poor powder flowability
limits delivery options

• Avoids cold storage
• Flowable powders allows
diverse delivery options

Spray drying: a process to engineer particles for
inhalation
Spray drying applied to live whole cells:
Drying Droplet

• Spray-drying BCG in salt-free suspensions minimizes
osmotic stresses during drying, thus minimizing loss of
bacterial viability *

• Microstructural properties adapted to optimize aerosol
properties
* Wong Y-L, et al. (2007) (2007) PNAS. 104, 2591

Preliminary results - Guinea pig study

• Influence of BCG vaccination by different routes on Tuberculin
reaction in guinea pigs *
Diameter of Induration (mm)
6 weeks after Vaccination
Treatment

Route of
administration

100 TU

BCG Powder

Pulmonary

18.60

2.61

11.80

1.92

BCG Solution

SC

17.83

1.83

11.33

3.14

Untreated

-

0

* Garcia-Contreras L, et al. (2008) PNAS. 105, 4656
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Preliminary results - Guinea pig study

• Number of viable bacteria per ml of tissue homogenate at necropsy
after bacterial challenge of animals immunized with BCG *

* Garcia-Contreras L, et al. (2008) PNAS. 105, 4656

Stability studies

• Stability of spray-dried BCG formulation after storage at 4˚C *

* Wong Y-L, et al. (2007) (2007) PNAS. 104, 2591

Technology transfer to South Africa

• Spray dry facility established in South Africa with funding from Bill
& Melinda Gates Foundation

• Focus: pharmaceutical development, production of material for
toxicology studies and Phase I human trials

• South Africa has a high burden of TB sufferers
• Local knowledge and close proximity to where the products will be
applied

• Availability of good infrastructure to support operation
• Establishing local expertise in pharmaceutical development of
inhalable drugs

Technology transfer to South Africa

• Spray drying process and some analytical methods transferred
• Further process and product optimization, validation of process and
analytical methods

• Product specifications: biological and physical properties for alveolar
delivery:
Physical property

Value

BCG content (wt%)

5

Viability (CFU/mg)

1-2x104

Geometric particle size distribution d50 (μm)

3-4

Aerodynamic particle size da (μm)

1.5-2.5

Fine particle fraction < 5.8 μm (%)

50

Density (g/cm3)

0.08-0.1

Moisture content (%)

0.1-0.5

The MEND spray drying facility

• Located at Medical Research Council in Pretoria
• Fully equipped for aseptic production, capsule filling and batch
release of whole-cell vaccines according to cGMP requirements

• All the equipment and analytical methods fully validated:





Andersen Cascade Impactor: aerodynamic particle size distribution
Sympatec HELOS/RODOS: geometric particle size distribution
Karl Fischer titrator: moisture content analysis
Waters HPLC: chemical composition

• Bioanalytical testing:




Viability determination in terms of ATP and CFU
Sterility
Live/dead assay

The MEND spray drying facility

• Laboratory conforming to OECD GLP and WHO BL3
requirements

G0018

Regulatory pathway
Fast-tracking BCG vaccine development:
Preclinical development

Initial formulations
Optimization
Aseptic capsule
filling studies
Analytical method
development
Stability testing
Production of tox
material and batch
release

Pre-IND meetings
with FDA and EMEA
Inhaler development

Toxicology study
In 2 animal models
IND meeting with
FDA and EMEA

Phase I clinical study

Summary

• MEND has a unique approach to apply Harvard University

•
•
•

technology to TB vaccine development in SA
BCG vaccine can be spray dried into viable aerosol with good long
term stability
Guinea pig studies show the viable BCG aerosol to be as
immunogenic as the intradermal control
Mend has established a GLP laboratory for production of material
for toxicology and Phase I human studies
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